Janux Therapeutics, Inc. Earnings Per Share, Basic and Diluted
Janux Therapeutics, Inc. (JANX) reported Earnings Per Share, Basic and Diluted of -$0.32 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-10.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-10
- Janux Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.32.
- Janux Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.32.
- Janux Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.26.
- Janux Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.62.
- Janux Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2021 was -$1.39.
- Janux Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2020 was -$7.41.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$0.32 10-Q · filed 2022-05-10 | -$0.65 derived: net income ÷ weighted average shares · filed 2023-05-09 | -$0.91 derived: net income ÷ weighted average shares · filed 2023-05-09 | -$1.31 derived: net income ÷ weighted average shares · filed 2023-05-09 |
| 2021-12-31 | -$0.32 derived: net income ÷ weighted average shares · filed 2023-03-10 | -$0.59 derived: net income ÷ weighted average shares · filed 2023-03-10 | -$0.98 derived: net income ÷ weighted average shares · filed 2023-03-10 | -$1.39 10-K · filed 2022-03-18 |
| 2021-09-30 | -$0.26 10-Q · filed 2021-11-09 | -$0.66 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$1.10 10-Q · filed 2021-11-09 | -$1.57 derived: net income ÷ weighted average shares · filed 2022-11-10 |
| 2021-06-30 | -$0.62 10-Q · filed 2021-08-10 | -$1.52 10-Q · filed 2021-08-10 | -$2.51 derived: net income ÷ weighted average shares · filed 2022-08-09 | -$3.48 derived: net income ÷ weighted average shares · filed 2022-08-09 |
| 2021-03-31 | -$2.06 10-Q · filed 2022-05-10 | -$3.72 derived: net income ÷ weighted average shares · filed 2022-05-10 | -$5.09 derived: net income ÷ weighted average shares · filed 2022-05-10 | -$7.75 derived: net income ÷ weighted average shares · filed 2022-05-10 |
| 2020-12-31 | -$1.65 derived: net income ÷ weighted average shares · filed 2022-03-18 | -$2.99 derived: net income ÷ weighted average shares · filed 2022-03-18 | -$5.68 derived: net income ÷ weighted average shares · filed 2022-03-18 | -$7.41 10-K · filed 2022-03-18 |
| 2020-09-30 | -$1.33 10-Q · filed 2021-11-09 | -$4.05 derived: net income ÷ weighted average shares · filed 2021-11-09 | -$5.79 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$2.76 10-Q · filed 2021-08-10 | -$4.52 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |